Evidence map›Paper›PMID 42039161›Full record

ArticleFrontiers in immunology2026

XIST expression and hypermethylation of the X chromosome in males with systemic lupus erythematosus.

Helen O Masson, Jonathan D Crawford, David C Gemperline, James E Scherschel, Guilherme G V Rocha, Christoph Preuss, Isabella H Wulur, Matthew D Linnik, Richard E Higgs, Ernst R Dow

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Helen O MassonEli Lilly and Company, Indianapolis, IN, United States.
Jonathan D CrawfordIndiana Biosciences Research Institute, Indianapolis, IN, United States.
David C GemperlineEli Lilly and Company, Indianapolis, IN, United States.
James E ScherschelEli Lilly and Company, Indianapolis, IN, United States.
Guilherme G V RochaEli Lilly and Company, Indianapolis, IN, United States.
Christoph PreussEli Lilly and Company, Indianapolis, IN, United States.
Isabella H WulurEli Lilly and Company, Indianapolis, IN, United States.
Matthew D LinnikEli Lilly and Company, Indianapolis, IN, United States.
Richard E HiggsEli Lilly and Company, Indianapolis, IN, United States.
Ernst R DowEli Lilly and Company, Indianapolis, IN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Systemic Lupus Erythematosus (SLE) exhibits a pronounced sex bias, affecting females approximately nine times more frequently than males; however, males tend to experience a more severe clinical course yet the molecular basis for these differences remains unclear. Methods: Leveraging epigenomic, transcriptomic, and proteomic data from the whole blood of 720 SLE patients (679 females, 41males) and 84 healthy controls (77 females, 7 males), we conducted comprehensive multi-omic analyses to identify sex-specific molecular features of this disease. Specifically, differential expression analysis for each modality was conducted using a factorial design to identify differences between disease and healthy controls (SLE-HC) for each sex, as well as the interaction effects between sex and disease ([Male SLE - Male HC] - [Female SLE - Female HC]). Benjamini & Hochberg false discovery rate (FDR) was used for multiple test correction. Results: The strongest signal differentiating males and females with SLE was the aberrant expression of the long non-coding RNA, Conclusion: These results suggest that X-chromosome silencing by

Indexed as

Chromosomes, Human, XDNA MethylationLupus Erythematosus, SystemicRNA, Long NoncodingAdultFemaleGene Expression ProfilingGene Expression RegulationHumansMaleSex FactorsX Chromosome InactivationRNA, Long NoncodingXIST non-coding RNAmulti-omicsexual dimorphismsystemic lupus erythematosus (SLE)X-chromosome inactivation (XCI)XIST

Identifiers

PMID42039161
PMCPMC13103550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.